2025-07-19 - Analysis Report
Okay, here's a report analyzing RXRX (Recursion Pharmaceuticals Inc.) based on the provided data.

**Report: Recursion Pharmaceuticals Inc. (RXRX) Analysis**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop novel medicines.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -45.96%
*   **VOO Cumulative Return:** 35.83%
*   **Deviation:** -81.79%
*   **Relative Deviation:** 1.9

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period for which data is available. The relative deviation of 1.9 indicates that RXRX's underperformance is near the bottom end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha   | Beta | Cap(B) |
| :---------- | :--- | :--- | :------ | :--- | :------ |
| 2021-2023  | 5.0% | 73.6% | -1.0%   | -0.1 | 4.3     |
| 2022-2024  | 0.0% | 73.6% | -25.0%  | 0.1  | 2.9     |
| 2023-2025  | 6.0% | 73.6% | -43.0%  | 0.1  | 2.5     |

**Analysis:**
*   **CAGR:**  CAGR is highly variable, showing inconsistent growth patterns.
*   **MDD:** The Maximum Drawdown is consistently high at 73.6%, indicating substantial risk and volatility.
*   **Alpha:**  Alpha is significantly negative, suggesting underperformance relative to the benchmark.
*   **Beta:** Beta is close to 0, indicating low correlation with the market.
*   **Cap:** The market capitalization has decreased over the period, reflecting potential investor concerns.

**2. Recent Price Action**

*   **Current Price:** $5.84
*   **Previous Close:** $5.52
*   **Change:** 5.8%
*   **5-Day Moving Average:** $5.45
*   **20-Day Moving Average:** $5.29
*   **60-Day Moving Average:** $4.98

**Analysis:** The stock is trading above its 5, 20, and 60-day moving averages, indicating a short-term upward trend. The significant change from the previous close ($5.8% increase) suggests a strong positive movement, possibly triggered by recent news or events.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 65.70 (Approaching Overbought)
*   **PPO:** 0.48
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** -1.5 (Negative - Short-term Decline)
*   **Expected Return:** -1352.7%

**Analysis:**
*   The MRI suggests low market risk, but the RSI is approaching overbought levels, which could indicate a potential pullback.
*   The Hybrid Signal recommends buying with caution.
*   The negative divergence suggests potential short-term weakness.
*   **The extremely negative expected return should be carefully scrutinized.** This value seems unrealistic.

The significant price change from the previous day's close indicates a notable event impacting the stock.

**4. Recent News & Significant Events**

*   **[2025-07-19]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-16]:** Analyst discussions on recent performance and outlook.
*   **[2025-07-17]:** Notable volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-15]:** Market experts highlight risks and opportunities.

**Analysis:** The news indicates that RXRX is experiencing significant activity and attention. Volatility is present, and analysts are actively discussing the company's prospects. Investors should carefully monitor company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
| :--------- | :---- | :---------- |
| 2025-05-05 | -0.50 | $0.01B     |
| 2024-11-06 | -0.34 | $0.03B     |
| 2024-08-08 | -0.40 | $0.01B     |
| 2024-05-09 | -0.39 | $0.01B     |
| 2025-05-05 | -0.39 | $0.01B     |

**Analysis:** RXRX is not yet profitable. EPS are consistently negative, and Revenue has been inconsistent.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |
| 2024-03-31 | $0.01B    | 17.23%        |

Capital and Profitability:

| Quarter    | Equity    | ROE      |
| :--------- | :-------- | :------- |
| 2025-03-31 | $0.93B    | -21.68%  |
| 2024-12-31 | $1.03B    | -17.29%  |
| 2024-09-30 | $0.52B    | -18.27%  |
| 2024-06-30 | $0.58B    | -16.69%  |
| 2024-03-31 | $0.40B    | -22.78%  |

**Analysis:** Revenue is inconsistent. Profit margins have been highly variable, with some quarters showing positive margins, but recent data indicates a drop. ROE is consistently negative. Equity has increased.

**7. Overall Summary**

RXRX has significantly underperformed the S&P 500.  The company is pre-profitability, and the financial data shows inconsistent performance. However, recent news suggests increased activity and analyst attention, potentially signaling a turning point. The recent price surge is a positive sign. Investors should proceed with caution, carefully monitoring news and company announcements. Given the volatile nature and the early stage of the company, investment in RXRX is high-risk.

**Key Concerns:**

*   Significant Underperformance vs. the market
*   Negative Earnings and Inconsistent Profitability
*   High Volatility

**Potential Positives:**

*   Recent Price Surge
*   Analyst Attention & News Activity
*   Low MRI

